TAOXHIGH SIGNALFINANCIAL10-K

TAOX experienced a dramatic deterioration in cash position alongside substantially reduced R&D spending and worsening operating losses.

The company's cash position declined from $17.7M to $5.5M while operating losses expanded to $9.0M, creating potential liquidity concerns given the current burn rate. The sharp reduction in R&D expenses suggests possible budget constraints that could impact the company's development pipeline and future growth prospects.

Comparing 2026-03-31 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

TAOX's financial position deteriorated meaningfully with cash reserves declining by nearly 70% to $5.5M while operating losses expanded to $9.0M from $6.8M. The company substantially reduced R&D spending, which fell to just $322K, likely reflecting cash conservation efforts. Despite the cash decline, total assets grew to $25.8M, suggesting potential asset revaluations or acquisitions, while total liabilities decreased significantly, indicating possible debt reduction or restructuring activities.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-79.8%
$1.6M$322K

R&D spending cut 79.8% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+78.8%
$1.0M$1.8M

Current liabilities surged 78.8% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-68.9%
$17.7M$5.5M

Cash declined 68.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-64.1%
$11.0M$3.9M

Liabilities reduced 64.1% — deleveraging improves balance sheet strength and financial flexibility.

Capital Expenditure
Cash Flow
-63.5%
$7K$3K

Capex reduced 63.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+45.7%
$17.7M$25.8M

Asset base grew 45.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+43.2%
$17.7M$25.4M

Current assets grew 43.2% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
-32.8%
-$6.8M-$9.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-30.9%
-$4.9M-$6.4M

Operating cash flow fell 30.9% — earnings quality concerns; investigate working capital changes and non-cash items.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-27
ADDED
(Exact name of registrant as specified in its charter) Delaware 46-1585656 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S.
As of March 30, 2026, the registrant had 7,471,931 shares of common stock outstanding.
Market For Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Management s Discussion and Analysis of Financial Condition and Results of Operations.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
+7 more — sign up free →
REMOVED
Synaptogenix, Inc._DECEMBER 31, 2024 0001571934 --12-31 2024 FY Synaptogenix, Inc.
( Exact name of registrant as specified in its charter) Delaware 46-1585656 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S.
As of March 27, 2025, the registrant had 1,389,815 shares of common stock outstanding.
Market For Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 60 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 60 Item 8.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →